Serotonin News and Research

Latest Serotonin News and Research

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that one in eight patients at risk of developing a serious adverse drug event is taking over-the-counter non-steroidal anti-inflammatory drugs, often to treat a musculoskeletal complaint.

13 Jun 2013

Scientists find that mice develop age-related progressive motor symptoms of Parkinson's disease

The presence of Lewy bodies in nerve cells, formed by intracellular deposits of the protein α-synuclein, is a characteristic pathologic feature of Parkinson's Disease (PD). In the quest for an animal model of PD that mimics motor and non-motor symptoms of human PD, scientists have developed strains of mice that overexpress α-synuclein.

10 Jun 2013

Common antidepressant medications may impair a form of learning, new report suggests

An interesting new report of animal research published in Biological Psychiatry suggests that common antidepressant medications may impair a form of learning that is important clinically.

10 Jun 2013

Study: Individuals with ASDs show decrease metabolism of amino acid L-tryptophan

Researchers at the JC Self Research Institute of the Greenwood Genetic Center (GGC), along with collaborators from Biolog, Inc. in California, have reported an important discovery in the understanding of autism which was published this week in Molecular Autism.

7 Jun 2013

GLYX-13 drug induces antidepressant results without street drug side effects

GLYX-13, a molecular cousin to ketamine, induces similar antidepressant results without the street drug side effects, reported a study funded by the National Institute of Mental Health (NIMH) that was published last month in Neuropsychopharmacology.

31 May 2013

Long-term depression linked with life-threatening chronic disease, earlier death

The first symptoms of major depression may be behavioral, but the common mental illness is based in biology — and not limited to the brain. In recent years some studies have linked major, long-term depression with life-threatening chronic disease and with earlier death, even after lifestyle risk factors have been taken into account.

23 May 2013

Antidepressant treatment results in lower rate of MSIMI

Among patients with stable coronary heart disease and mental stress-induced myocardial ischemia (MSIMI), 6 weeks of treatment with the antidepressant escitalopram, compared with placebo, resulted in a lower rate of MSIMI, according to a study in the May 22/29 issue of JAMA.

22 May 2013

UTMB researchers awarded grant to study gene therapy techniques to eliminate neuropathic pain

University of Texas Medical Branch at Galveston researchers have been awarded a five-year, $1.8 million grant by the National Institute of Neurological Disorders and Stroke to apply the techniques of gene therapy to the problem of neuropathic pain - that is, pain that arises from a malfunction in the nervous system.

21 May 2013

Patients with treatment-resistant depression benefit from ketamine

Patients with treatment-resistant major depression saw dramatic improvement in their illness after treatment with ketamine, an anesthetic, according to the largest ketamine clinical trial to-date led by researchers from the Icahn School of Medicine at Mount Sinai.

20 May 2013

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Takeda Pharmaceutical Company Limited and H. Lundbeck A/S today announced that the companies will be presenting new data from four studies that evaluated effectiveness in treating the overall symptoms of depression in patients taking vortioxetine, an investigational agent under review with the U.S. Food and Drug Administration for the treatment of major depressive disorder.

20 May 2013

Depression and time perception: an interview with Dr Rachel Msetfi, University of Limerick

In clinical terms, depression is defined by the presence of a cluster of symptoms. The Diagnostic Manual used by many psychologists and psychiatrists cites nine symptoms of depression, of which five must be present for a two-week period.

16 May 2013

Findings could help develop new approaches to treat depression and memory loss in the elderly

Scientists have known for some time that exercise induces neurogenesis in a specific brain region, the hippocampus. However, until this study, the underlying mechanism was not fully understood.

14 May 2013

New challenges to military medicine

Better body armor and rapid aeromedical evacuations enable American service members to survive blasts that would have proved fatal in Vietnam or even the first Gulf War, but they pose new challenges to military medicine - how to deal with the excruciating pain of injuries, especially severe burns from IED blasts that body armor can't protect.

13 May 2013

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

Peripheral neuropathic pain is caused by lesion or disease to the peripheral somatosensory nervous system. Nerve damage that can lead to peripheral neuropathic pain can happen as a result of a range of different diseases, medications or traumatic injuries.

8 May 2013

SSRIs associated with increased risk of bleeding, transfusion, readmission and death

Selective serotonin reuptake inhibitors (SSRIs) - among the most widely prescribed antidepressant medications - are associated with increased risk of bleeding, transfusion, hospital readmission and death when taken around the time of surgery, according to an analysis led by researchers at UC San Francisco and Baystate Medical Center in Springfield, Mass.

30 Apr 2013

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

Alkermes plc (NASDAQ: ALKS) today announced positive preliminary topline results from a phase 2 study of ALKS 5461, its novel drug compound for major depressive disorder (MDD) in patients who have an inadequate response to standard therapies for clinical depression.

22 Apr 2013

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

ADial Pharmaceuticals, LLC, announced today that the U.S. Food and Drug Administration has agreed to allow ADial to move forward with its plan to initiate Phase III trials of AD04 as a treatment for alcohol use disorder in certain targeted genotypes population only.

19 Apr 2013

Serotonin News and Research

Latest Serotonin News and Research

Study shows 1 in 8 patients at risk of developing serious ADE take OTC NSAIDs

Scientists find that mice develop age-related progressive motor symptoms of Parkinson's disease

Common antidepressant medications may impair a form of learning, new report suggests

Study: Individuals with ASDs show decrease metabolism of amino acid L-tryptophan

GLYX-13 drug induces antidepressant results without street drug side effects

Long-term depression linked with life-threatening chronic disease, earlier death

Antidepressant treatment results in lower rate of MSIMI

UTMB researchers awarded grant to study gene therapy techniques to eliminate neuropathic pain

Patients with treatment-resistant depression benefit from ketamine

Takeda, Lundbeck announce presentation of data from four studies that evaluate vortioxetine for MDD

Depression and time perception: an interview with Dr Rachel Msetfi, University of Limerick

Findings could help develop new approaches to treat depression and memory loss in the elderly

New challenges to military medicine

Peripheral neuropathic pain patch treatments: an interview with Anne Hodgkins, Astellas Pharma

SSRIs associated with increased risk of bleeding, transfusion, readmission and death

Alkermes reports topline results from phase 2 study of ALKS 5461 drug for major depressive disorder

FDA agrees to allow ADial to move forward with Phase III trial of AD04 for alcohol use disorder

REFRESH study: RP5063 shows promise for schizophrenia and schizoaffective disorder

Nine Nobel laureates to present their research at American Chemical Society meeting

Duloxetine drug alleviates pain from chemotherapy

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Serotonin News and Research

Latest Serotonin News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in